HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Seiji Yano Selected Research

Meningeal Carcinomatosis

9/2021Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
1/2020Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.
1/2017MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer.
1/2016High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells.
10/2009Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Seiji Yano Research Topics

Disease

133Neoplasms (Cancer)
07/2022 - 06/2002
72Lung Neoplasms (Lung Cancer)
02/2022 - 06/2002
43Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2022 - 06/2002
37Neoplasm Metastasis (Metastasis)
10/2022 - 01/2002
14Malignant Mesothelioma
09/2021 - 01/2006
13Small Cell Lung Carcinoma (Small Cell Lung Cancer)
07/2017 - 01/2003
11Adenocarcinoma of Lung
02/2020 - 06/2002
7Carcinoma (Carcinomatosis)
12/2020 - 11/2010
7Pleural Effusion (Pleural Effusions)
09/2017 - 01/2006
6Stomach Neoplasms (Stomach Cancer)
01/2022 - 01/2003
6Pancreatic Neoplasms (Pancreatic Cancer)
09/2021 - 04/2003
6Adenocarcinoma
07/2015 - 04/2004
5Prostatic Neoplasms (Prostate Cancer)
10/2021 - 04/2004
5Meningeal Carcinomatosis
09/2021 - 10/2009
5Disease Progression
06/2021 - 11/2014
5Brain Neoplasms (Brain Tumor)
08/2020 - 01/2002
4Peritoneal Neoplasms
01/2022 - 06/2011
4Squamous Cell Carcinoma (Epidermoid Carcinoma)
12/2020 - 06/2002
4Mesothelioma
10/2020 - 06/2002
4Hemorrhage
07/2019 - 07/2002
4Malignant Pleural Effusion
02/2007 - 06/2003
3Ascites
01/2022 - 06/2011
3Renal Cell Carcinoma (Grawitz Tumor)
11/2021 - 12/2010
3Colonic Neoplasms (Colon Cancer)
10/2021 - 03/2005
3Thyroid Neoplasms (Thyroid Cancer)
01/2021 - 01/2019
3Carcinogenesis
12/2020 - 01/2018
3Breast Neoplasms (Breast Cancer)
12/2013 - 01/2003
3Neoplasm Micrometastasis
07/2011 - 03/2003
3Pancreatic Ductal Carcinoma
09/2005 - 04/2003
3Ductal Carcinoma
09/2005 - 04/2003
2Melanoma (Melanoma, Malignant)
01/2022 - 08/2020
2Retinoblastoma (Glioblastoma, Retinal)
10/2021 - 03/2005

Drug/Important Bio-Agent (IBA)

47Tyrosine Kinase InhibitorsIBA
06/2022 - 05/2003
41ErbB Receptors (EGF Receptor)IBA
09/2021 - 01/2003
31Gefitinib (Iressa)FDA Link
01/2022 - 05/2003
20Phosphotransferases (Kinase)IBA
01/2022 - 01/2004
18Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2022 - 06/2003
18Proteins (Proteins, Gene)FDA Link
10/2021 - 01/2003
16Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
01/2022 - 11/2008
16Erlotinib Hydrochloride (CP 358,774)FDA Link
10/2020 - 11/2008
14Pharmaceutical PreparationsIBA
01/2022 - 03/2003
14osimertinibIBA
01/2022 - 01/2016
13CrizotinibIBA
10/2020 - 07/2012
11alectinibIBA
06/2022 - 07/2014
8LigandsIBA
09/2021 - 11/2008
7Anaplastic Lymphoma KinaseIBA
06/2022 - 07/2012
7Cisplatin (Platino)FDA LinkGeneric
09/2012 - 11/2004
6Biological ProductsIBA
01/2022 - 04/2003
6Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2019 - 04/2003
6tyrosine receptor (receptor, tyrosine)IBA
01/2018 - 07/2013
5Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
07/2022 - 12/2013
5Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
01/2022 - 01/2006
5Diphosphonates (Bisphosphonates)IBA
03/2016 - 01/2003
4RNA (Ribonucleic Acid)IBA
02/2022 - 04/2017
4AfatinibIBA
01/2022 - 03/2012
4AndrogensIBA
01/2021 - 06/2006
4VorinostatFDA Link
02/2020 - 04/2013
4lenvatinibIBA
07/2019 - 12/2009
4Bevacizumab (Avastin)FDA Link
12/2015 - 10/2007
4Neutralizing AntibodiesIBA
09/2012 - 02/2004
4CytokinesIBA
09/2011 - 03/2003
4Parathyroid Hormone-Related ProteinIBA
01/2009 - 02/2004
3entrectinibIBA
07/2022 - 12/2017
3Immune Checkpoint InhibitorsIBA
06/2022 - 02/2020
3trametinibIBA
09/2021 - 01/2018
3Etoposide (VP 16)FDA LinkGeneric
02/2021 - 11/2003
3EnzymesIBA
01/2021 - 02/2007
3Biomarkers (Surrogate Marker)IBA
12/2020 - 09/2011
3DNA (Deoxyribonucleic Acid)IBA
08/2020 - 04/2004
3Histone Deacetylase InhibitorsIBA
01/2020 - 01/2018
3AmphiregulinIBA
01/2020 - 06/2011
3Peptides (Polypeptides)IBA
01/2020 - 10/2009
3Docetaxel (Taxotere)FDA Link
10/2019 - 03/2003
3CateninsIBA
01/2019 - 08/2015
3Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
01/2017 - 07/2012
3AntibodiesIBA
01/2015 - 12/2011
3WZ4002IBA
01/2013 - 03/2012
3Cetuximab (Erbitux)FDA Link
11/2012 - 06/2011
3Tyrosine (L-Tyrosine)FDA Link
07/2011 - 01/2005
3YM 529IBA
01/2009 - 01/2003
3GemcitabineFDA Link
01/2009 - 08/2005
3Therapeutic UsesIBA
01/2009 - 07/2002
3vandetanib (ZD6474)IBA
06/2008 - 12/2005
3N- (2- chloro- 5- methoxyphenyl)- 6- methoxy- 7- ((1- methyl- 4- piperidinyl) methoxy) 4-quinazolinamineIBA
09/2006 - 01/2005
3src-Family KinasesIBA
09/2006 - 01/2005
3Oxygen (Dioxygen)IBA
04/2006 - 07/2002
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2006 - 01/2003
3Matrix Metalloproteinases (MMPs)IBA
03/2003 - 10/2002
2Axitinib (AG 013736)IBA
10/2022 - 01/2020
2MicroRNAs (MicroRNA)IBA
05/2022 - 10/2019
2Messenger RNA (mRNA)IBA
01/2022 - 06/2011
2NivolumabIBA
01/2022 - 12/2020
2Oncogene Proteins (Oncogene Protein)IBA
01/2022 - 11/2008

Therapy/Procedure

48Therapeutics
01/2022 - 01/2002
22Drug Therapy (Chemotherapy)
06/2021 - 07/2002
4Combination Drug Therapy (Combination Chemotherapy)
12/2020 - 09/2004
3Radiotherapy
10/2022 - 08/2005
2Aftercare (After-Treatment)
02/2022 - 09/2012
2Nephrectomy
11/2021 - 11/2010
2Castration
10/2021 - 05/2010